Sonrotoclax Joins the BCL-2 Toolkit With a Two-Line BTK Gate
The FDA's May 13 accelerated approval of sonrotoclax is real but small — two prior lines including a BTK inhibitor, 52 percent response, a confirmatory trial still pending.
Kenji Nakamura
Bureau: Tokyo
Daraxonrasib's Pancreatic-Cancer Result Is Now in the NEJM Record
The NEJM publication of Phase 1/2 daraxonrasib data is the durable record — line of therapy and grade-three adverse events are what patients should read.